Sr One Capital buys Zenas Biopharma (ZBIO) shares worth $2.4 million

Published 14/10/2025, 22:22
© Reuters

SR One Capital Management, along with Simeon George, reported purchasing shares of Zenas BioPharma Inc (NASDAQ:ZBIO) on October 9, 2025. The purchases, made at a price of $19 per share, totaled $2399985. The stock, currently trading at $25.76, has shown remarkable momentum with a 27% gain in the past week. According to InvestingPro data, analysts maintain a strong buy consensus with price targets ranging from $24 to $45.

The transactions involved the acquisition of 63,158 shares and 63,157 shares of common stock. The company, now valued at $1.12 billion, maintains a strong balance sheet with more cash than debt. Want deeper insights? InvestingPro offers 11 additional investment tips for ZBIO.

In other recent news, Zenas Biopharma has entered a significant licensing agreement with InnoCare Pharma, granting Zenas global rights to develop and commercialize three autoimmune product candidates, including orelabrutinib, a BTK inhibitor in Phase 3 development for multiple sclerosis. The agreement involves Zenas paying InnoCare up to $100 million in cash for upfront and near-term milestone payments, alongside up to 7 million shares of Zenas common stock. The total potential value of the deal exceeds $2 billion when considering development, regulatory, and commercial milestones. H.C. Wainwright has maintained a Buy rating on Zenas Biopharma, citing the company’s pipeline expansion following this agreement. The firm has set a price target of $30.00 for Zenas Biopharma. Meanwhile, Zeta Network Group has announced a strategic partnership with SOLV Foundation to enhance its Bitcoin-centric financial initiatives. This partnership will utilize SOLV’s platform, which holds $2.5 billion in total value locked, to optimize Zeta Network Group’s Bitcoin holdings. The Bitcoin assets will be managed under the custody of a regulated third-party custodian to ensure transparency and auditability.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.